The approval of brensocatib for use in patients with bronchiectasis could offer the first treatment directly addressing the ...

An estimated 5.17% of patients with inflammatory bowel diseases also have bronchiectasis, as shown in chest CT scans of patients with IBD.

Bronchiectasis is a chronic airway suppurative disease in which recurrent airway infections, inflammation and remodeling have ...

The drug is manufactured by the US firm Insmed and made possible after 15 years of research by scientists from the University ...

Long-term antibiotics use carries the risk of resistance and side effects, representing a gap in the market for a different ...

Karnataka reports third COVID-19 fatality in 2025, with patient succumbing to septic shock and pneumonia despite vaccination.

Experts at the University of Dundee have announced promising results from a clinical trial of a potential new antibody ...

Bronchiectasis impacts up to 500,000 Americans, but there is often misdiagnosis or delayed diagnosis as the condition can present similarly to other pulmonary conditions such as COPD or asthma.

The article titled "Effects of the DPP-1 Inhibitor HSK31858 in Adults with Bronchiectasis in China (SAVE-BE): A Phase 2, Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial," focuses ...

Targeting airway inflammation with investigational brensocatib reduced exacerbations with bronchiectasis, the ASPEN trial showed. The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized ...

Discover how HSK31858 could transform bronchiectasis treatment by reducing flare-ups - read more about the latest trial results.

For patients with bronchiectasis, brensocatib leads to a lower annualized rate of pulmonary exacerbations, according to a study published in the April 24 issue of the New England Journal of Medicine.